Jasper Therapeutics Inc (JSPR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.18M
Last updated: Nov 17, 2026 at 11:05 AM ET
Jasper Therapeutics Inc (JSPR) Stock Forecast
Analysts expect Jasper Therapeutics (JSPR) to earn -$6.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.00M. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$21.15.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$6.90
- EPS consensus, revenue $6.00M
- Fiscal year ending Dec 31, 2027
- -$21.15
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$6.90 | -$12.30 to -$1.50 | 2 | $6.00M | N/A | 2 |
| Dec 31, 2027 | -$21.15 | -$39.30 to -$3.00 | 2 | N/A | N/A | 2 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$9.08 | -$13.52 to -$2.84 | 7 |
Estimate Revisions
No EPS estimate for the 2 periods below was revised in the last 30 days.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$72.30.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$6.90 | -$42.30 | -$72.30 | -$72.30 | -$72.30 | N/A |
| Fiscal year ending Dec 31, 2027 | -$21.15 | -$58.05 | -$76.80 | -$76.80 | -$76.80 | N/A |
Frequently Asked Questions About JSPR
What is the JSPR stock forecast?
Consensus analyst estimates put Jasper Therapeutics's EPS at -$6.90 for the fiscal year ending Dec 31, 2026, on revenue of $6.00M.
What EPS do analysts expect from JSPR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$6.90, with estimates from -$12.30 to -$1.50 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$21.15, with estimates from -$39.30 to -$3.00 from 2 analysts.
What revenue do analysts expect from Jasper Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.00M.
How many analysts cover JSPR?
2 analysts estimate EPS for Jasper Therapeutics for the fiscal year ending Dec 31, 2026.
JSPR pages: Overview, Earnings, Forecast, Financials, Competitors